Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Sarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Fluorouracil 498Bevacizumab 476Oxaliplatin 450Leucovorin 442Irinotecan 408Cetuximab 318Capecitabine 317pembrolizumab 142Folfox protocol 128Panitumumab 117regorafenib 105Colonoscopy 88Nivolumab 82IFL protocol 81Drug Therapy 77trifluridine tipiracil drug combination 73Radiotherapy 66HMPL-013 65Blood Specimen Collection 52Gemcitabine 49Specimen Handling 47Standard of Care 45Neoadjuvant Therapy 45Magnetic Resonance Spectroscopy 44Biopsy 44Chemotherapy, Adjuvant 41Trifluridine 40atezolizumab 39Cyclophosphamide 39Surveys and Questionnaires 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × pidilizumab × Clear all
NCT00890305 2015-07-08

Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone

Medivation, Inc.

Phase 2 Completed
171 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡